Literature DB >> 24386015

Radiation therapy is well tolerated and produces excellent control rates in elderly patients with locally advanced head and neck cancers.

Omar K Jilani1, Prabhsimranjot Singh1, A Gabriella Wernicke1, David I Kutler2, William Kuhel2, Paul Christos3, Dattatreyudu Nori1, Albert Sabbas1, Ks Clifford Chao1, Bhupesh Parashar1.   

Abstract

PURPOSE: Management of locally advanced head and neck cancer (LAHNC) in the elderly is challenging due to multiple co-morbidities, poor organ function and performance status. The aim of this study was to evaluate efficacy of radiation therapy (RT) in elderly patients, defined as 65 years and older, with high-risk LAHNC.
MATERIALS AND METHODS: An IRB approved retrospective chart review of elderly patients was performed, of whom 73 patients were selected for analysis. The stages included were II/III-IV. Sites included were oropharynx, oral cavity, larynx, salivary gland, nasopharynx, nasal cavity, paranasal sinus, hypopharynx and unknown primary.
RESULTS: Median age was 74 years. Thirty nine (53%) patients received concurrent chemotherapy. Median time to completion of RT was 53 days. Median external beam radiotherapy (EBRT) dose was 66 Gy. With a median follow-up of 24 months, overall local control (LC) was 80% and distant metastasis (DM) was 12%. Sixty patients (82%) were alive at the time of study. Two-year overall survival (OS) was 96% (95% CI=87%, 99%). Chemotherapy did not improve LC [80% (chemo) vs 79% (no chemo), p=0.88] or DM [11% (chemo) vs 14% (no chemo), p=0.73]. Interestingly, patients receiving RT using intensity-modulated radiation therapy (IMRT) had a significantly higher rate of LC vs three-dimensional conformal radiotherapy (3DCRT) (94% vs 68%, respectively, p=0.008). Grade 2/3 toxicity was seen in 70/73 (96%) patients while grade 4 toxicity was seen in three patients (4%).
CONCLUSION: Elderly patients with LAHNC have high rates of LC and OS. Prospective studies can reveal more insight into this increasingly important clinical problem in elderly patients.

Entities:  

Keywords:  3D; Head and Neck; IMRT; elderly; radiation

Year:  2012        PMID: 24386015      PMCID: PMC3876481          DOI: 10.1016/j.jgo.2012.05.001

Source DB:  PubMed          Journal:  J Geriatr Oncol        ISSN: 1879-4068            Impact factor:   3.599


  22 in total

1.  Selective organ preservation in operable locally advanced head and neck squamous cell carcinomas guided by primary site restaging biopsy: long-term results of two sequential brown university oncology group chemoradiotherapy studies.

Authors:  Harold J Wanebo; Ritesh Rathore; Prakash Chougule; Michael R DiSiena; R James Koness; Robert G McRae; Peter T Nigri; Kathy Radie-Keane; Neal Ready
Journal:  Ann Surg Oncol       Date:  2011-05-07       Impact factor: 5.344

2.  Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel : a phase II study.

Authors:  Robert Semrau; Susanne Temming; Simon Florian Preuss; Jens Peter Klubmann; Orlando Guntinas-Lichius; Rolf-Peter Müller
Journal:  Strahlenther Onkol       Date:  2011-09-23       Impact factor: 3.621

3.  Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.

Authors:  Jochen H Lorch; Olga Goloubeva; Robert I Haddad; Kevin Cullen; Nicholas Sarlis; Roy Tishler; Ming Tan; John Fasciano; Daniel E Sammartino; Marshall R Posner
Journal:  Lancet Oncol       Date:  2011-01-11       Impact factor: 41.316

Review 4.  Treatment considerations for head and neck cancer in the elderly.

Authors:  Eric M Genden; Alessandra Rinaldo; Ashok R Shaha; Gary L Clayman; Jochen A Werner; Carlos Suárez; Alfio Ferlito
Journal:  J Laryngol Otol       Date:  2005-03       Impact factor: 1.469

5.  Intensity-modulated radiotherapy in patients with head and neck cancer: a European single-centre experience.

Authors:  D Van Gestel; D Van Den Weyngaert; D Schrijvers; J Weyler; J B Vermorken
Journal:  Br J Radiol       Date:  2011-04       Impact factor: 3.039

6.  Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).

Authors:  Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre
Journal:  Head Neck       Date:  2005-10       Impact factor: 3.147

Review 7.  Optimizing systemic therapy in squamous cell carcinoma of the head and neck with a focus on targeted agents.

Authors:  Nabil F Saba; Fadlo R Khuri
Journal:  Curr Opin Oncol       Date:  2009-05       Impact factor: 3.645

Review 8.  Chemotherapeutic management of stage IV non-small cell lung cancer.

Authors:  Mark A Socinski; David E Morris; Gregory A Masters; Rogerio Lilenbaum
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

9.  Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience.

Authors:  Alexandra D Jensen; Zazie P Bergmann; Helena Garcia-Huttenlocher; Kolja Freier; Jürgen Debus; Marc W Münter
Journal:  Head Neck Oncol       Date:  2010-11-26

Review 10.  Oropharyngeal cancer: the role of chemotherapy.

Authors:  David J Adelstein
Journal:  Curr Treat Options Oncol       Date:  2003-02
View more
  1 in total

1.  Tolerance of Radical Radiotherapy Among Elderly Head and Neck Cancer Patients.

Authors:  A S Kirthi Koushik; K S Sandeep; M G Janaki; Ram Charith Alva; Irappa Vithoba Madabhavi
Journal:  Indian J Surg Oncol       Date:  2020-01-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.